Gaps in prevention are not frequently due to a complete lack of information, but instead the fact that organizations don't have a clear way to see how the pieces fit together until after an incident has occurred.
VBC aligns reimbursements to outcomes, emphasizing the quality and effectiveness, not quantity, of healthcare activities. But the same cost constraints driving interest in VBC can also turn it into a liability.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps.
When used thoughtfully, with attention to muscle preservation and long-term sustainability, medical weight loss can lower complication rates, support a steadier recovery and reduce downstream strain on both patients and health systems.
The core challenge for leadership is no longer merely managing direct vendors; it’s the cascading risk of the "nth-party" supplier.
Confirmed diversion cases do not equal true prevalence - they are directly dependent on investigative proficiency, tooling, and the bandwidth of the teams doing the work.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
We should never wait for tragedies to force a conversation around clear governance and accountability. Oversight has to evolve alongside innovation to protect people before harm occurs.
As an industry, we need to ask hard questions. Are delegated vendors delivering on the promise of better, faster, more transparent decisions? Or are they simply moving the pain to another part of the system?
With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.
As healthcare continues to become more and more dependent on third-party vendor services, provider and technology entities must remain focused on the risks that their vendors present.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Behavioral health doesn’t need tech that replaces people. It needs technology that respects them, amplifying what clinicians do best and helping more people get the care they deserve.
By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge.
By integrating industry standards into e-prescribing software, prescribing organizations can reduce errors to improve patient outcomes and lessen the burden of medication-related errors on healthcare systems. Here’s a look at the new National Council for Prescription Drug Programs (NCPDP) Sig Standard aimed at improving prescription accuracy.
While new technologies may demonstrate clinical benefits in controlled settings, their true value is determined by how well they fit into existing healthcare workflows.
A culture of compliance means truly valuing an adherence to industry standards, rather than looking at SOPs as a series of boxes that need to be checked in order to claim that requirements have been met.